Literature DB >> 28696844

Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.

Mohammad T Hojjati1, Azita Azarkeivan2, Ali A Pourfathollah1, Naser Amirizadeh1.   

Abstract

Drug induction of Hb F seems to be an ideal therapy for patients with hemoglobin (Hb) disorders, and many efforts have been made to reveal the mechanism behind it. Thus, we examined in vivo expression of some microRNAs (miRNAs) that are thought to be involved in this process. Among β-thalassemia (β-thal) patients who were undergoing hydroxyurea (HU) therapy in the past 3 months and five healthy individuals, five responders and five non-responders, were also included in the study. Erythroid progenitors were isolated by magnetic activated cell sorting (MACS) and miRNA expression analyzed using reverse transcription-polymerase chain reaction (RT-PCR). We showed that γ-globin, miR-210 and miR-486-3p had higher levels in the responders than the non-responders group. Moreover, miR-150 and miR-320 had higher levels in the healthy group than both non-responders and responders groups, but the expression of miR-96 did not show any significant difference between the study groups. To the best of our knowledge, this is the first study proposing that 'induction of cellular hypoxic condition by Hb F inducing agents' could be the milestone of possible mechanisms that explain why responders are able to reactivate γ-globin genes and subsequently, more production of Hb F, in response to these agents in comparison to non-responders. However, further investigations need to be performed to verify this hypothesis.

Entities:  

Keywords:  hydroxyurea (HU); hypoxia; microRNA (miRNA); β-Thalassemia (β-thal); γ-globin

Mesh:

Substances:

Year:  2017        PMID: 28696844     DOI: 10.1080/03630269.2017.1290651

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  5 in total

Review 1.  A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Authors:  Nirmani Yasara; Anuja Premawardhena; Sachith Mettananda
Journal:  Orphanet J Rare Dis       Date:  2021-03-01       Impact factor: 4.123

2.  MIR29B mediates epigenetic mechanisms of HBG gene activation.

Authors:  Athena Starlard-Davenport; Alana Smith; Luan Vu; Biaoru Li; Betty S Pace
Journal:  Br J Haematol       Date:  2019-03-19       Impact factor: 6.998

3.  Epigenetic effects toward new insights as potential therapeutic target in B-thalassemia.

Authors:  Noha Hamdy Eltaweel; Ghada Youssef ElKamah; Rabab Khairat; Hanan Abd Elmawgoud Atia; Khalda S Amr
Journal:  J Genet Eng Biotechnol       Date:  2021-03-31

Review 4.  Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option.

Authors:  Athena Starlard-Davenport; Qingqing Gu; Betty S Pace
Journal:  Mol Diagn Ther       Date:  2022-05-12       Impact factor: 4.476

Review 5.  Hemoglobinopathies in Iran: An Updated Review.

Authors:  Abolfazl Nasiri; Zohreh Rahimi; Asad Vaisi-Raygani
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.